Last Price
6.84
Today's Change
+0.547 (8.68%)
Day's Change
6.11 - 7.06
Trading Volume
35,697
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Alexander Y. Tokman Mr. Alexander Y. Tokman
Full Time Employees: 21 21
IPO Date: 2017-06-30 2017-06-30
CIK: 0001681682 0001681682
ISIN: US29273B3024 US29273B3024
CUSIP: 29273B104 29273B104
Beta: 0.74 0.74
Last Dividend: 0.00 0.00
Dcf Diff: 6.03 6.03
Dcf: 0.27 0.27
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.